ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RENX Renalytix Plc

33.50
-1.50 (-4.29%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50 -4.29% 33.50 32.00 35.00 35.00 33.50 35.00 92,711 16:26:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Services, Nec 3.4M -46.22M -0.4626 -0.72 33.48M
Renalytix Plc is listed in the Services sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix was 35p. Over the last year, Renalytix shares have traded in a share price range of 10.25p to 145.00p.

Renalytix currently has 99,930,156 shares in issue. The market capitalisation of Renalytix is £33.48 million. Renalytix has a price to earnings ratio (PE ratio) of -0.72.

Renalytix Share Discussion Threads

Showing 451 to 475 of 2800 messages
Chat Pages: Latest  28  27  26  25  24  23  22  21  20  19  18  17  Older
DateSubjectAuthorDiscuss
22/7/2020
07:57
This video shows very succinctly why PYC could be worth MULTIPLES of 100p

Tempus is a $5bn startup targeting 'Personalised Precision Oncology'

If they are serious (they certainly sound like it) they or others in this huge emerging field will have to snap up a Company with the specialist knowledge / Virtual Tumour model and relationships Physiomics have built over 20 years IMO



Why PYC could be the RENX of Cancer AI

the stigologist
22/7/2020
07:56
This video shows very succinctly why PYC could be worth MULTIPLES of 100p

Tempus is a $5bn startup targeting 'Personalised Precision Oncology'

If they are serious (they certainly sound like it) they or others in this huge emerging field will have to snap up a Company with the specialist knowledge / Virtual Tumour model and relationships Physiomics have built over 20 years IMO



Why PYC could be the RENX of Cancer AI

the stigologist
22/7/2020
07:35
With the closing of the global offering, I am interested to see if Renalytix increase their 'initial' equity interest in Kantaro Bioscience.

Given the relationship, I am also interested to see whether the approved test dovetails with with Mount Sinai's efforts in developing AI to help diagnose and treat Covid-19, which make sense, or indeed whether Renalytix extends their reach to COVID-19 AI related diagnostics -

Mount Sinai Center Developing AI to Help Diagnose, Treat Covid-19
COVID Informatics Center aims to help the hospital network make more efficient use of its resources
By Elliot M. Kass
July 16, 2020


New York's Mount Sinai gets Microsoft grant for COVID-19 data center:
Laura Dyrda (Twitter)
Tuesday, June 9th, 2020

New York City-based Mount Sinai Health System received a grant for an undisclosed amount from Microsoft for its new COVID-19 data science center.

Four things to know:

1. Microsoft AI for Health awarded the Mount Sinai COVID Informatics Center a grant and cloud resources to accelerate discovery, translation and digital tool implementation.

2. The new center focuses on developing tools using artificial intelligence that will enhance evidence-based medicine related to COVID-19 treatment. It will use Microsoft Azure cloud computing for complex patient data storage.

3. Mount Sinai aims to rapidly develop digital health products with real-time predictive and preventive capabilities at the new center, which recently launched a study to monitor the biometrics of healthcare workers using Apple watches. These efforts will help the system understand the stress and anxiety healthcare works face on the front lines.

4. The grant also will support the health system develop an infrastructure to improve patient outcomes after the pandemic.

wan
22/7/2020
06:13
hxxps://stocktwits.com/Stocktwits
This one is good but no page yet.

mr roper
22/7/2020
05:32
Agree good to have an up finish 👍🏼
Does any one know which share chat sites are the most active in the Us? Trying to find some forums over there to monitor local discussions

2theduke
21/7/2020
21:26
Agree, however they initially stated that they would submit it for FDA approval by the end of May & it ended up being 17th June, which I suspect was partly tactical. Let’s see! Ps. Nice to see us close at $14 on NASDAQ, volume has been decent so far too.
74tom
21/7/2020
21:10
Can’t imagine you get a choice on timing that Rns . But let’s hope you’re right
2theduke
21/7/2020
16:48
Global offering now closed, I’d say the decks are now clear for newsflow - they clearly weren’t going to announce the antibody approval in the midst of the IPO...
74tom
21/7/2020
15:35
not in their hands - waiting for regulatory approval?
nimbo1
21/7/2020
15:31
They’re getting a bit late on the anti body test update, given kantaro still states a lunch in July...
2theduke
21/7/2020
14:20
There will be plenty of pi's selling because it didn't double day one.

They need to execute from an operational perspective - as and when they do share price will increase dramatically I would have thought. We are now tied to the nasdaq price and other than the insti's who purchased shares over there no other investors have heard of renx yet.

Im sure when Stifel resume coverage and put out an investment note / renx release their first news on nasdaq you'll see interest pick up. also the share price has travelled quite a long way relatively quickly - you always get periods of distribution after such times...especially after raising money!

The key thing is they have their money so the potential to be a great success is now in their hands : )

nimbo1
21/7/2020
14:11
It baffles me that anyone would want to sell right now, you can bet your bottom dollar that they’ll have strong newsflow lined up for the next few months to support the NASDAQ listing. I’ve added some more today, looking forward to the ride :)
74tom
21/7/2020
13:26
For newbies to Physiomics (PYC) it is worth reading the 'Plain English Summary' on the Government NIHR (National Institute for Health Research) website detailing what their Precision Personalised Oncology Tool is about. This is just their 'first' tool aimed at Prostate Cancer. Expect more in future with the ultimate goal being a complete 'Cancer Decision Support System' tool to help front line clinicians decide best treatment regimens for Patients (ideally based on their individual genotype / phenotype)
the stigologist
21/7/2020
09:47
UK Govt has funded PYC VT model to tune of £0.5m so far

Imagine if UK Govt had invested £0.5m in likes of AVCT GDR ODX NCYT. It's not just the money but validation which speaks volumes

the stigologist
20/7/2020
13:18
Deep Dive Into Big Pharma AI Productivity: One Study Shaking The Pharmaceutical Industry



Very interesting on how early stage this move to AI is in Pharma and how slow moving Big Pharma is

How they are very slow to take on board outside technology (a great feather in PYC cap they have got into Merck KGaA and others)

Merck KGaA clearly leading edge and punching well above their weight in AI adoption

Another validation of PYC

Getting another Large Pharma on board could be start of a domino effect/tsunami of contracts/revenue growth over coming years

the stigologist
20/7/2020
11:57
Toffeeman - True, basic error on my part!
hpcg
20/7/2020
10:39
Another 4 from my listening - but would need to listen again to double check.
nimbo1
20/7/2020
10:22
Is that another 3 or another 4 Nimbo?
melody9999
20/7/2020
09:49
The UK research (on research tree) has revenue predictions of $24 million for this full year just entered - that depends on when Mount Sinai goes commercial during the next few months of course but the revenue is just anticipated from that 1 installation. In the US IPO presentation they state they expect to have another 4 up and running within 12 months. So theoretically annualised revenue could be c.$125 million when all of those are up and running.

Clearly at the moment pre revenue a lot is taken on trust and you have to buy into the story and execution operationally - however if the above happens you'll see a $1billion market cap here within 12 months...and they'll still only be scratching the surface of the ultimate market and potential. Everything normally takes longer than expected!

Mount Sinai coming into the fund raise was very important ref confidence from my own perspective.

nimbo1
20/7/2020
09:33
Need to think of the current price as ex-Verici.
toffeeman
20/7/2020
08:52
I've bought more here, though at the top end of the spread. Logical resting place, but not factoring in the US investors are simply a lot more bullish on growth than UK investors.
hpcg
20/7/2020
08:26
I’m a buyer at this level
volsung
20/7/2020
08:22
my sense is that this is probably the wrong time to be selling any. the share price is at the NASDAQ placing price which should act as a floor; US buyers should now start to take up stock and we can expect further newsflow on KidneyIntel; in addition the RNS on 20/5 referred to the COVID-19 scaled kit production starting in July to enable clinical laboratories to conduct 10M tests per month.
melody9999
20/7/2020
08:09
If by magic the price had opened this morning at £50, you would have PI’s that would buy shares, the same goes for if they opened at 50p, a number would sell... shares price behaviour is a fascinating insight into human psychology!
74tom
20/7/2020
07:45
Almost at the placing price - makes sense! I’ll probably buy some more but now have to decide where. Coverage in the US not good yet - no stocktwits page for example (their equivalent of advfn).

Certainly some selling by pi’s going on - probably the ones that pushed the price to 625!

nimbo1
Chat Pages: Latest  28  27  26  25  24  23  22  21  20  19  18  17  Older

Your Recent History

Delayed Upgrade Clock